The goal of EMPA-ELDERLY, the first randomized clinical study of an SGLT2 inhibitor in elderly T2D patients, was to increase the evidence supporting the use of SGLT2 inhibitors while also assessing the impact on muscle mass and muscle strength [39]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.